MedCity News November 16, 2023
FDA approval of Bristol Myers Squibb’s Augtyro covers treatment of patients whose non-small cell lung cancer is driven by the rare ROS1 mutation. The molecule comes from BMS’s 2022 acquisition of Turning Point Therapeutics.
Immunotherapy is finding use in more cancers and as an earlier line of cancer treatment, as Bristol Myers Squibb knows well with its three FDA-approved checkpoint inhibitors. But for some cancers, a targeted therapy remains the first choice. The latest BMS approval is for a drug targeted to a particular genetic mutation already addressed by drugs from Pfizer and Roche. But BMS believes its new drug is a superior option.
The FDA has approved BMS’s repotrectinib as a treatment for non-small cell lung cancer (NSCLC) driven...
Today's Sponsors
Today's Sponsor